Future neuroprotective strategies in the post-thrombolysis era - Neurovascular unit protection and vascular endothelial protection

Tatsushi Kamiya, Koji Abe

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

From an appearance of recombinant tissue plasminogen activator (rt-PA) in the clinical therapy on 2005 in Japan, the therapeutic strategy of ischemic stroke therapy is now changing dramatically. Many experimental data from animal stroke and clinical trials of neuroprotective agents failed to clinical useful therapeutic strategy. A free radical scavenger, edaravone is the first clinical drug for neuroprotection in the world which has been used in almost all ischemic stroke patients in Japan from 2001. Now, it is especially useful in thrombolytic therapy with rt-PA, whereas we still need the newly more effective neuroprotective drugs which can be applied to many ischemic stroke patients. Therefore, we review and describe the future neuroprotective strategies in the post-thrombolysis era.

Original languageEnglish
Pages (from-to)305-315
Number of pages11
JournalClinical Neurology
Volume51
Issue number5
DOIs
Publication statusPublished - May 2011

Fingerprint

Blood Vessels
Stroke
Neuroprotective Agents
Tissue Plasminogen Activator
Japan
Free Radical Scavengers
Thrombolytic Therapy
Therapeutics
Clinical Trials
Pharmaceutical Preparations

Keywords

  • Acute ischemic stroke
  • Ischemic cell death
  • Neuroprotection
  • Therapeutic time window
  • Thrombolysis

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Future neuroprotective strategies in the post-thrombolysis era - Neurovascular unit protection and vascular endothelial protection. / Kamiya, Tatsushi; Abe, Koji.

In: Clinical Neurology, Vol. 51, No. 5, 05.2011, p. 305-315.

Research output: Contribution to journalArticle

@article{2412f2dd0dc046a88c52c8e39ec13309,
title = "Future neuroprotective strategies in the post-thrombolysis era - Neurovascular unit protection and vascular endothelial protection",
abstract = "From an appearance of recombinant tissue plasminogen activator (rt-PA) in the clinical therapy on 2005 in Japan, the therapeutic strategy of ischemic stroke therapy is now changing dramatically. Many experimental data from animal stroke and clinical trials of neuroprotective agents failed to clinical useful therapeutic strategy. A free radical scavenger, edaravone is the first clinical drug for neuroprotection in the world which has been used in almost all ischemic stroke patients in Japan from 2001. Now, it is especially useful in thrombolytic therapy with rt-PA, whereas we still need the newly more effective neuroprotective drugs which can be applied to many ischemic stroke patients. Therefore, we review and describe the future neuroprotective strategies in the post-thrombolysis era.",
keywords = "Acute ischemic stroke, Ischemic cell death, Neuroprotection, Therapeutic time window, Thrombolysis",
author = "Tatsushi Kamiya and Koji Abe",
year = "2011",
month = "5",
doi = "10.5692/clinicalneurol.51.305",
language = "English",
volume = "51",
pages = "305--315",
journal = "Clinical Neurology",
issn = "0009-918X",
publisher = "Societas Neurologica Japonica",
number = "5",

}

TY - JOUR

T1 - Future neuroprotective strategies in the post-thrombolysis era - Neurovascular unit protection and vascular endothelial protection

AU - Kamiya, Tatsushi

AU - Abe, Koji

PY - 2011/5

Y1 - 2011/5

N2 - From an appearance of recombinant tissue plasminogen activator (rt-PA) in the clinical therapy on 2005 in Japan, the therapeutic strategy of ischemic stroke therapy is now changing dramatically. Many experimental data from animal stroke and clinical trials of neuroprotective agents failed to clinical useful therapeutic strategy. A free radical scavenger, edaravone is the first clinical drug for neuroprotection in the world which has been used in almost all ischemic stroke patients in Japan from 2001. Now, it is especially useful in thrombolytic therapy with rt-PA, whereas we still need the newly more effective neuroprotective drugs which can be applied to many ischemic stroke patients. Therefore, we review and describe the future neuroprotective strategies in the post-thrombolysis era.

AB - From an appearance of recombinant tissue plasminogen activator (rt-PA) in the clinical therapy on 2005 in Japan, the therapeutic strategy of ischemic stroke therapy is now changing dramatically. Many experimental data from animal stroke and clinical trials of neuroprotective agents failed to clinical useful therapeutic strategy. A free radical scavenger, edaravone is the first clinical drug for neuroprotection in the world which has been used in almost all ischemic stroke patients in Japan from 2001. Now, it is especially useful in thrombolytic therapy with rt-PA, whereas we still need the newly more effective neuroprotective drugs which can be applied to many ischemic stroke patients. Therefore, we review and describe the future neuroprotective strategies in the post-thrombolysis era.

KW - Acute ischemic stroke

KW - Ischemic cell death

KW - Neuroprotection

KW - Therapeutic time window

KW - Thrombolysis

UR - http://www.scopus.com/inward/record.url?scp=79959458284&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959458284&partnerID=8YFLogxK

U2 - 10.5692/clinicalneurol.51.305

DO - 10.5692/clinicalneurol.51.305

M3 - Article

C2 - 21706826

AN - SCOPUS:79959458284

VL - 51

SP - 305

EP - 315

JO - Clinical Neurology

JF - Clinical Neurology

SN - 0009-918X

IS - 5

ER -